The forward P/E of 21.14 implies the market expects earnings to grow roughly 60% from current levels, a steep assumption given the cyclicality of credit data demand. The EV/EBITDA of 14.43 is above TransUnion's 13.59, but the gap narrows on forward EV/EBITDA (12.49 vs. 13.59), suggesting investors are paying up for Equifax's faster growth. However, the PEG of 7.33 is elevated, indicating that the current growth rate may already be fully reflected in the price, leaving little room for disappointment.

The stability of gross margins despite revenue acceleration suggests Equifax is not sacrificing pricing to drive growth, a positive sign for earnings quality. Operating margin expansion from 16.2% to 18.5% over the past year indicates that SG&A costs are growing slower than revenue, a trend that could continue if revenue growth persists. However, the 2025Q4 gross margin of 11.0% appears to be a data anomaly, and investors should monitor whether this represents a one-time charge or a structural shift.

The persistently low ROIC suggests that Equifax's acquisitions have not yet generated returns commensurate with the capital deployed, as goodwill of $6.8B represents over half of total assets. While ROE has ticked up to 4.0%, it remains well below the cost of equity, implying that the company is not compounding shareholder value at an attractive rate. The improvement in ROE is driven by margin expansion and buybacks, but the underlying return on capital remains constrained by the intangible-heavy balance sheet.

The improvement in DSO from 63 to 58 days indicates that Equifax is collecting receivables faster, which is a positive sign for cash flow. However, the current ratio of 0.60 is well below 1.0, meaning current liabilities exceed current assets, a common trait for companies with strong cash flow but heavy debt. The lack of DIO data limits a full CCC analysis, but the stable DPO around 17-29 days suggests Equifax is not stretching supplier payments, which may indicate a conservative approach to working capital.

Interest coverage has improved from 3.79 to 5.25 over the past two years, indicating that Equifax's earnings are increasingly sufficient to service its debt. However, the D/EBITDA ratio of 10.81 is extremely high, suggesting that debt levels are substantial relative to cash flow, which could become a concern if revenue growth stalls. The gradual increase in D/E from 1.19 to 1.21, coupled with a shrinking equity base due to buybacks, indicates that leverage is creeping higher, and investors should monitor refinancing risk given the thin cash buffer of $170M.

The current ratio of 0.60 suggests that Equifax would struggle to cover short-term obligations with current assets alone, a common situation for companies with strong cash flow but heavy debt. However, the company's operating cash flow consistently exceeds net income, with OCF/NI averaging 2.2, which provides a buffer. The lack of inventory means the quick ratio equals the current ratio, so there is no inventory cushion, but the stable cash conversion cycle and strong OCF may mitigate liquidity stress in the near term.

The valuation premium over TransUnion is not justified by current profitability, as Equifax's ROE and ROIC are significantly lower. However, Equifax's revenue growth is accelerating, which may warrant a premium if the growth is sustainable. The gap in ROE is likely due to Equifax's larger goodwill base and higher leverage, which are structural rather than operational. Investors should monitor whether Equifax can close the ROE gap through margin expansion and efficient capital deployment.